Prophylactic effect of antiretroviral therapy on hepatitis B virus infection

Clinical Infectious Diseases

Volumn 56, Issue 12, 2013, Pages 1812-1819

  Gatanaga, Hiroyuki ^a,b   Hayashida, Tsunefusa ^a,b   Tanuma, Junko ^a   Oka, Shinichi ^a,b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

chronic infection; lamivudine; resistant; tenofovir disoproxil fumarate

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TENOFOVIR DISOPROXIL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; DRUG USE; FOLLOW UP; GENOTYPE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

CHRONIC INFECTION; LAMIVUDINE; RESISTANT; TENOFOVIR DISOPROXIL FUMARATE;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTI-RETROVIRAL AGENTS; ANTIBIOTIC PROPHYLAXIS; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; MALE; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES;

EID: 84878267931     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit145     Document Type: Article

References (40)

1. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306-10.
2. Lacombe K, Bottero J, Lemoine M, et al. HIV/hepatitis B virus co-infection: current challenges and new strategies. J Antimicrob Chemo-ther 2010; 65:10-7.
3. Soriano V, Vispo E, Labarga P, et al. Viral hepatitis and HIV co-infection. Antiviral Res 2010; 85:303-15.
4. Kourtis AP, Bulterys M, Hu DJ, et al. HIB-HBV coinfection-a global challenge. N Engl J Med 2012; 366:1749-52.
5. Kellerman SE, Hanson DL, McNaghten AD, et al. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188:571-7.
6. Lincoln D, Petoumenos K, Dore GJ, et al. HIV/HBV and HIV/HCV co-infection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4:241-9.
7. Nunez M, Soriano V. Management of hepatitis co-infected with hepatitis B virus and HIV. Lancet Infect Dis 2005; 6:374-82.
8. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med 2007; 356:1445-54.
9. Hattori J, Shiino T, Gatanaga H, et al. Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antivir Res 2010; 88:72-9.
10. Fujisaki S, Yokomaku Y, Shiino T, et al. Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. J Clin Microbiol 2011; 49:1017-24.
11. Thio CL, Seaberg EC, Skolasky RL, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002; 360:1921-6.
12. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 49:S138-45.
13. Brook G, Main J, Nelson M, et al. British HIV association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med 2010; 11:1-30.
14. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International AIDS Society-USA panel. JAMA 2012; 308:387-402.
15. Kinn S, Akhavan S, Agut H, et al. Performance of the DiaSorin LIAISON anti-HBs II for the detection of hepatitis B surface antibodies: comparison with the Abbott ARCHITECT anti-HBs assay. J Clin Virol 2011; 50:297-302.
16. Ollier L, Laffont C, Kechkekian A, et al. Detection of antibodies to hepatitis B core antigen using the Abbott ARCHITECT anti-HBc assay: analysis of borderline reactive sera. J Virol Methods 2008; 154:206-9.
17. Tadokoro K, Kobayashi M, Yamaguchi T, et al. Classification of hepatitis B virus genotypes by the PCR-invader method with genotype-specific probes. J Virol Methods 2006; 138:30-9.
18. Tadokoro K, Suzuki F, Kobayashi M, et al. Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay. J Virol Methods 2011; 171:67-73.
19. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137:1593-608.
20. Koibuchi T, Hitani A, Nakamura T, et al. Predominance of genotype A HBV in an HBV-HIV-1 dually positive population compared with an HIV-1-negative counterpart in Japan. J Med Virol 2001; 64:435-40.
21. Matsuura K, Tanaka Y, Hige S, et al. Distribution of hepatitis B virus genotypes with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol 2009; 47:1476-83.
22. Kobayashi M, Ikeda K, Arase Y, et al. Change of hepatitis B virus genotypes in acute and chronic infections in Japan. J Med Virol 2008; 80:1880-4.
23. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011; 26:S123-30.
24. Gandhi RT, Wurcel A, Lee H, et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis 2003; 36:1602-5.
25. French AL, Operskalski E, Peters M, et al. Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolve hepatitis C virus infection in a cohort of US women. J Infect Dis 2007; 195:1437-42.
26. Perez-Rodriguez MT, Sopena B, Crespo M, et al. Clinical significance of "anti-HBc alone" in human immunodeficiency virus-positive patients. World J Gastroenterol 2009; 15:1237-41.
27. Koo YX, Tan DS, Tan IB, et al. "Anti-HBc alone" in human immunodeficiency virus-positive and immune-suppressed lymphoma patients. World J Gastroenterol 2009; 15:3834-5.
28. Gandhi RT, Wurcel A, Lee H, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005; 191:1435-41.
29. French AL, Lin MY, Evans CT, et al. Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women. Clin Infect Dis 2009; 49:148-54.
30. Biggar RJ, Goedert JJ, Hoofnagle J. Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV. N Engl J Med 1987; 316:630-1.
31. Collier AC, Corey L, Murphy VL, et al. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med 1988; 109:101-5.
32. Loke RH, Murray-Lyon IM, Coleman JC, et al. Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: an indicator of poor prognosis. J Med Virol 1990; 31:109-11.
33. Tayal SC, Sankar KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS 1994; 8:558-9.
34. del Pozo Balado Mdel M, Leal M, Mendez Lagares G, et al. Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine. J Infect Dis 2010; 202:362-9.
35. Fonseca MO, Pang LW, de Paula Cavalheiro N, et al. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23: 2902-8.
36. Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunoge-nicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011; 305:1432-40.
37. Flynn PM, Cunningham CK, Rudy B, et al. Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. J Acquir Immune Defic Syndr 2011; 56:325-32.
38. Wilson DP, Law MG, Grulich AE, et al. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008; 372: 314-20.
39. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
40. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylax-is for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.